GSK1324726A (I-BET726)
-
GSK1324726A (I-BET726)
structure -
-
CAS No:
1300031-52-0
-
Formula:
C25H23ClN2O3
-
Chemical Name:
GSK1324726A (I-BET726)
-
Synonyms:
GSK1324726A;4-[(2S,4R)-1-Acetyl-4-[(4-chlorophenyl)amino]-2-methyl-1,2,3,4-tetrahydro-6-quinolinyl]benzoic acid;GSK1324726A (I-BET726);4-((2S,4R)-1-acetyl-4-(4-chlorophenylamino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid;4-[(2S,4R)-1-Acetyl-4-[(4-chlorophenyl)amino]-1,2,3,4-tetrahydro-2-methyl-6-quinolinyl]benzoic acid
- Categories:
-
CAS No:
Drug Information
4-(1-acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid
GSK1324726A (I-BET726) Use and Manufacturing
Procedure 24-{(2S.4/?)-1 -Acetyl-4-r(4-chlorophenyl)aminol-2-methyl-1.2.3.4-tetrahvdro-6- quinolinvDbenzoic acidEthyl 4-{(2S, 4R)-1 -acetyl-4-[(4-chlorophenyl)amino]-2-methyl-1 , 2, 3, 4-tetrahydro-6- quinolinyl}benzoate (for a preparation see Example 158) (5.41 g, 1 1.69 mmol) was dissolved in ethanol (100 mL) and the solution was treated with 2M NaOH aqueous solution (50 mL, 100 mmol). The resulting mixture was stirred at room temperature (air atmosphere) for approximately 2 h then most of the ethanol was removed in vacuo. The resulting yellow solution was diluted with water (resulting in the formation of an oily yellow precipitate). The aqueous phase was washed twice with DCM (which didn't dissolve the precipitate previously formed) then was acidified with a 2N hydrochloric acid aqueous solution to pH 1 and extracted twice with AcOEt. The combined AcOEt phases were washed with brine, dried using a hydrophobic frit and concentrated in vacuo. The residual yellow foam was triturated with EtEthyl 4-{(2S, 4R)-1 -acetyl-4-[(4-chlorophenyl)amino]-2-methyl-1 , 2, 3, 4-tetrahydro-6- quinolinyl}benzoate (for a preparation see Intermediate 17) (5.41 g, 1 1.69 mmol) was dissolved in ethanol (100 mL) and the solution was treated with aqueous NaOH solution (2M, 50 mL, 100 mmol). The resulting mixture was stirred at room temperature (air atmosphere) for approximately 2 h then most of the ethanol was removed in vacuo. The resulting yellow solution was diluted with water (resulting in the formation of an oily yellow precipitate). The aqueous phase was washed twice with DCM (which didn't dissolve the precipitate previously formed) then was acidified with hydrochloric acid (2N) to pH 1 and extracted with EtOAc (x2). The combined EtOAc phases were washed with brine, dried (hydrophobic frit) and concentrated in vacuo. The residual yellow foam was triturated with EtEthyl 4-{(2S, 4R)-1 -acetyl-4-[(4-chlorophenyl)amino]-2-methyl-1 , 2, 3, 4-tetrahydro-6- quinolinyl}benzoate (for a preparation see Intermediate 17) (5.41 g, 1 1.69 mmol) was dissolved in ethanol (100 mL) and the solution was treated with aqueous NaOH solution (2M, 50 mL, 100 mmol). The resulting mixture was stirred at room temperature (air atmosphere) for approximately 2 h then most of the ethanol was removed in vacuo. The resulting yellow solution was diluted with water (resulting in the formation of an oily yellow precipitate). The aqueous phase was washed twice with DCM (which didn't dissolve the precipitate previously formed) then was acidified with hydrochloric acid (2N) to pH 1 and extracted with EtOAc (x2). The combined EtOAc phases were washed with brine, dried (hydrophobic frit) and concentrated in vacuo. The residual yellow foam was triturated with EtIntermediate 18 4-{(2S, 4R)-1-Acetyl-4-[(4-chlorophenyl)amino]-2-methyl-1, 2, 3, 4-tetrahydro-6-quinolinyl}benzoic acid [0199] [0200] Ethyl 4-{(2S, 4R)-1-acetyl-4-[(4-chlorophenyl)amino]-2-methyl-1, 2, 3, 4-tetrahydro-6-quinolinyl}benzoate (for a preparation see Intermediate 17) (5.41 g, 11.69 mmol) was dissolved in ethanol (100 mL) and the solution was treated with aqueous NaOH solution (2M, 50 mL, 100 mmol). The resulting mixture was stirred at room temperature (air atmosphere) for approximately 2 h then most of the ethanol was removed in vacuo. The resulting yellow solution was diluted with water (resulting in the formation of an oily yellow precipitate). The aqueous phase was washed twice with DCM (which didn't dissolve the precipitate previously formed) then was acidified with hydrochloric acid (2N) to pH 1 and extracted with EtOAc (×2). The combined EtOAc phases were washed with brine, dried (hydrophobic frit) and concentrated in vacuo. The residual yellow foam was triturated with Et[0125] A solution of Intermediate 8 (320mg, 0.73 mmol) in EtOH (10ml) and 1N NaOH (1.5ml, 1.5mmol) was heatedto reflux. After 1 hour a tlc monitoring indicated the completion of the reaction. The crude mixture was evaporated todryness and the residue taken up in water (10mL). Acidification of the mixture at pH=3 was carried out by addition of a1N HCl solution. The organic materials were extracted with EtOAc (3x 25 mL) and the organic phase combined andwashed with brine and dried over Na2SO4. After concentration under vacuo the residue was taken up in a DCM/ hexanemixture to give a red solid after filtration. The compound was recrystallised in EtOAC, filtered and washed with i-Pr2O.The resulting white powder was solubilised in MeOH/H2O, concentrated to dryness and taken up with H2O. Finallyfiltration of the precipitate afforded the title compound as a white powder (147mg), mp: 275°C.HRMS calculated for C25H23N2O3Cl (M-H)- 433.1319, found : 433.1299. Rt: 2.21 min.1 H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.2 (d, 3 H) 1.35 (m, 1 H) 2.3 (s, 3 H) 2.7 (m, 1 H) 4.25 (dd, 1 H) 4.95(m, 1 H) 6.65 (d, 2 H) 7.15 (d, 2 H) 7.25 (s, 1 H) 7.55 (m, 4 H), 8.15(d, 2H)[α]D = + 395 (c= 0.96 g/cl, EtOH) measured at the EtOAc recrystallisation stage.The title compound eluted at 4.51 min by HPLC as the first peak using a Chiralpak IA (250x4.6 mm 5mm) column withtert-butyl methyl oxide (MTBE) +0.1percent TFA /Ethanol :90/10 as the mobile phase. A 1 ml/mn flow rate was applied and10mL of sample prepared with the dilution of 1 mg of the title compound in 1ml of eluent was injected. Detection of thecompound was carried out with both 210 and 254 nM UV wavelengths. The other enantiomer came off at 5.92 min.Pd/C (22.1 mg, 10percent, 0.208 mmol, containing -50percent water) was added to a solution of 4- ((2S, 4R)-1-acetyl-4-((4-chlorophenyl)amino)-2-methyl-1 , 2, 3, 4-tetrahydroquinolin-6- yl)benzoic acid (for a preparation see Intermediate 18)(369 mg, 0.848 mmol) and ammonium formate (134 mg, 2.121 mmol) in ethanol (5 ml) and DMF (1 ml) and reaction mixture heated at reflux. After 1.5h the reaction mixture was cooled to r.t.. The reaction mixture was filtered through Celite.(TM). and filter cake washed with EtOH. The filtrate was concentrated to give a light brown oil (251 mg). The filter cake was washed with a further portion of 1 :1 EtOH:DMF (50ml) and combined with the previous material and concentrated to give 4-((2S, 4R)-1 -acetyl-2-methyl-4-(phenylamino)-1 , 2, 3, 4- tetrahydroquinolin-6-yl)benzoic acid (306mg, 0.764mmol, 90percent yield) as a yellow solid. LCMS (Formate, 2min), Rt=1.01 min, MH+ = 401.
Computed Properties
Molecular Weight:434.9
XLogP3:5.1
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:4
Rotatable Bond Count:4
Exact Mass:434.1397203
Monoisotopic Mass:434.1397203
Topological Polar Surface Area:69.6
Heavy Atom Count:31
Complexity:643
Defined Atom Stereocenter Count:2
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Recommended Suppliers of GSK1324726A (I-BET726)
-
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives
Latest News on GSK1324726A (I-BET726)
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
Dabrafenib
1195765-45-7
-
BOC-VAL-VAL-OH
69209-73-0
-
BMS 303141
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula
57899-96-4
-
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Formula
26130-02-9
-
L-Tyrosyl-L-phenylalanine Structure
17355-11-2
-
C-REACTIVE PROTEIN FRAGMENT 77-82 Structure
130349-01-8
-
What is Sildenafil
139755-83-2
-
What is Dacomitinib
1110813-31-4